| 1 |
34717125 | PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation. | 2022 Jan 5 |
4 |
| 2 |
35177427 | mCRPC patients receiving 225Ac-PSMA-617 therapy in post androgen deprivation therapy setting: Response to treatment and survival analysis. | 2022 Feb 17 |
1 |
| 3 |
35631549 | Development and Evaluation of a PSMA-Targeted Nanosystem Co-Packaging Docetaxel and Androgen Receptor siRNA for Castration-Resistant Prostate Cancer Treatment. | 2022 Apr 29 |
1 |
| 4 |
33315676 | Docetaxel-Induced Interstitial Pneumonitis Detected on 68Ga-PSMA PET/CT. | 2021 May 1 |
1 |
| 5 |
33538232 | Glutamate-urea-based PSMA-targeted PLGA nanoparticles for prostate cancer delivery of docetaxel. | 2021 Apr |
3 |
| 6 |
33682320 | UpFrontPSMA: a randomized phase 2 study of sequential 177 Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol). | 2021 Sep |
1 |
| 7 |
33778927 | Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer. | 2021 Mar 29 |
1 |
| 8 |
33783752 | Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer? | 2021 Jun |
3 |
| 9 |
34473816 | All-purpose nanostrategy based on dose deposition enhancement, cell cycle arrest, DNA damage, and ROS production as prostate cancer radiosensitizer for potential clinical translation. | 2021 Sep 2 |
2 |
| 10 |
34772793 | 68Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy. | 2021 Nov 12 |
2 |
| 11 |
34804839 | Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer. | 2021 Oct |
1 |
| 12 |
32333064 | [PSMA radioligand therapy in patients with advanced prostate cancer]. | 2020 Jun |
1 |
| 13 |
32595026 | Assessment of the role of Ga-68 PSMA I&T PET/CT in response evaluation to docetaxel therapy in castration resistant prostate cancer patients. | 2020 Sep - Oct |
2 |
| 14 |
30606553 | Development of PSMA-targeted and core-crosslinked glycol chitosan micelles for docetaxel delivery in prostate cancer therapy. | 2019 Mar |
1 |
| 15 |
30663074 | Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer. | 2019 May |
1 |
| 16 |
31069008 | 177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer. | 2019 Mar 29 |
1 |
| 17 |
29185010 | Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. | 2018 Apr |
1 |
| 18 |
29978216 | Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial. | 2018 Oct 1 |
4 |
| 19 |
28128882 | Co-Delivery of Docetaxel and p44/42 MAPK siRNA Using PSMA Antibody-Conjugated BSA-PEI Layer-by-Layer Nanoparticles for Prostate Cancer Target Therapy. | 2017 May |
1 |
| 20 |
26847057 | Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors. | 2016 Jul 1 |
1 |
| 21 |
27058278 | PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer. | 2016 Aug 1 |
7 |
| 22 |
27393562 | Aptamer-mediated delivery of docetaxel to prostate cancer through polymeric nanoparticles for enhancement of antitumor efficacy. | 2016 Oct |
1 |
| 23 |
21750220 | In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen. | 2011 Sep |
1 |
| 24 |
18698158 | Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). | 2008 Jun |
1 |
| 25 |
16606824 | Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. | 2006 Apr 18 |
2 |